The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities

Developmental Biology

Volumn 411, Issue 2, 2016, Pages 287-293

  Stewart, Elizabeth ^a   Federico, Sara ^a   Karlstrom, Asa ^a   Shelat, Anang ^a   Sablauer, Andras ^a   Pappo, Alberto ^a   Dyer, Michael A ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Childhood solid tumors; Epigenomics; Genetically engineered mouse models; Genomics; Xenograft

Indexed keywords

ARTICLE; CANCER CELL LINE; CHILDHOOD CANCER; DEVELOPMENTAL BIOLOGY; DRUG SCREENING; DRUG SENSITIVITY; EWING SARCOMA; GENETIC PROCEDURES; GENETICALLY ENGINEERED MOUSE STRAIN; HEPATOBLASTOMA; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MOUSE MODEL; NEUROBLASTOMA; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PHARMACOKINETICS; PRIORITY JOURNAL; RETINOBLASTOMA; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR MODEL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WHOLE GENOME SEQUENCING; ANIMAL; CANCER TRANSPLANTATION; CHILD; EPIGENETICS; GENETIC ENGINEERING; GENETICS; GENOMICS; INFANT; MEDICAL RESEARCH; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASM; NEWBORN; PRESCHOOL CHILD; TRANSGENIC MOUSE; TRENDS; TUMOR CELL LINE;

ANIMALS; BIOMEDICAL RESEARCH; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; EPIGENOMICS; GENETIC ENGINEERING; GENOMICS; HEPATOBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; MELANOMA; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEUROBLASTOMA; OSTEOSARCOMA; RETINOBLASTOMA; RHABDOMYOSARCOMA; SARCOMA, EWING;

EID: 84959482267     PISSN: 00121606     EISSN: 1095564X     Source Type: Journal    
DOI: 10.1016/j.ydbio.2015.03.001     Document Type: Article

References (62)

1. Abramson D.H., Ronner H.J., Ellsworth R.M. Second tumors in nonirradiated bilateral retinoblastoma. Am. J. Ophthalmol. 1979, 87:624-627.
2. Applebaum M.A., et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011, 117:3027-3032. 10.1002/cncr.25840.
3. Barr F.G. Chromosomal translocations involving paired box transcription factors in human cancer. Int. J. Biochem. Cell Biol. 1997, 29:1449-1461.
4. Benavente C.A., et al. Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget 2013, 4:844-859.
5. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
6. Cepko C.L., Austin C.P., Yang X., Alexiades M., Ezzeddine D. Cell fate determination in the vertebrate retina. Proc. Natl. Acad. Sci. USA 1996, 93:589-595.
7. Chen X., et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013, 24:710-724. 10.1016/j.ccr.2013.11.002.
8. Chen X., et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014, 7:104-112. 10.1016/j.celrep.2014.03.003.
9. Chen X., Pappo A.S., Dyer M.A. Pediatric solid tumor genomics and developmental pliancy. Oncogene 2015, in preparation.
10. Chen Y., et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455:971-974. 10.1038/nature07399.
11. Cheung N.K., et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. J. Am. Med. Assoc. 2012, 307:1062-1071. 10.1001/jama.2012.228.
12. Cheung N.K., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013, 13:397-411. 10.1038/nrc3526.
13. Chow K.L., Masland R.H., Stewart D.L. Receptive field characteristics of striate cortical neurons in the rabbit. Brain Res. 1971, 33:337-352.
14. Delattre O., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992, 359:162-165. 10.1038/359162a0.
15. Downing J.R., et al. The pediatric cancer genome project. Nat. Genet. 2012, 44:619-622. 10.1038/ng.2287.
16. Dyer, M., 2015. In: Chalupa, L., Williams R., (Eds.), Eye, Retina, and Visual System of the Mouse, MIT Press, in press.
17. Dyer M.A., Bremner R. The search for the retinoblastoma cell of origin. Nat. Rev. Cancer 2005, 5:91-101.
18. Finegold M.J., et al. Protocol for the examination of specimens from pediatric patients with hepatoblastoma. Arch. Pathol. Lab. Med. 2007, 131:520-529. 10.1043/1543-2165(2007)131[520:PFTEOS]2.0.CO;2.
19. George R.E., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455:975-978. 10.1038/nature07397.
20. Hatley M.E., et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell 2012, 22:536-546. 10.1016/j.ccr.2012.09.004.
21. Hicks M.J., Roth J.R., Kozinetz C.A., Wang L.L. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2007, 25:370-375. 10.1200/JCO.2006.08.4558.
22. Johnson D., et al. Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res. 2007, 67:2701-2711.
23. Kleinerman R.A., et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2005, 23:2272-2279. 10.1200/JCO.2005.05.054.
24. Lessnick S.L., Ladanyi M. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets. Annu. Rev. Pathol. 2012, 7:145-159. 10.1146/annurev-pathol-011110-130237.
25. London W.B., et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2005, 23:6459-6465. 10.1200/JCO.2005.05.571.
26. Lopez-Terrada D., et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum. Pathol. 2009, 40:783-794. 10.1016/j.humpath.2008.07.022.
27. Lu C., et al. The genomic landscape of childhood and adolescent melanoma. J. Investig. Dermatol. 2015, in press.
28. Macpherson D., Dyer M.A. Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res. 2007, 67:7547-7550.
29. McEvoy J., et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011, 20:260-275. 10.1016/j.ccr.2011.07.005.
30. McEvoy J., et al. RB1 inactivation by chromothripsis in human retinoblastoma. Oncotarget 2015, in press.
31. McIntyre J.F., et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 1994, 12:925-930.
32. Meyers P.A., et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J. Clin. Oncol. 1993, 11:449-453.
33. Miller C.W., et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res. 1990, 50:7950-7954.
34. Missiaglia E., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012, 30:1670-1677. 10.1200/JCO.2011.38.5591.
35. Molenaar J.J., et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet. 2012, 44:1199-1206. 10.1038/ng.2436.
36. Mosse Y.P., et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 2004, 75:727-730. 10.1086/424530.
37. Mosse Y.P., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455:930-935. 10.1038/nature07261.
38. Mosse Y.P., et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr. Blood Cancer 2014, 61:627-635. 10.1002/pbc.24777.
39. Newton W.A., et al. Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 1988, 6:67-75.
40. Ognjanovic S., Linabery A.M., Charbonneau B., Ross J.A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009, 115:4218-4226. 10.1002/cncr.24465.
41. Pappo A.S. Melanoma in children and adolescents. Eur. J. Cancer 2003, 39:2651-2661.
42. Perilongo G., Shafford E.A. Liver tumours. Eur. J. Cancer 1999, 35:953-958.
43. Raabe E.H., et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 2008, 27:469-476. 10.1038/sj.onc.1210659.
44. Raney R.B., et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 2001, 23:215-220.
45. Reis S.M., et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 1999, National Cancer Institute (SEER Program), Bethesda, MD, NIH Publication no. 99-4649.
46. Sausen M., et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 2013, 45:12-17. 10.1038/ng.2493.
47. Schulte J.H., et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 2012, 32:1059-1065. 10.1038/onc.2012.106.
48. Scrable H., et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc. Natl. Acad. Sci. USA 1989, 86:7480-7484.
49. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2:731-737.
50. Spector L.G., Birch J. The epidemiology of hepatoblastoma. Pediatr. Blood Cancer 2012, 59:776-779. 10.1002/pbc.24215.
51. Stahl M., et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr. Blood Cancer 2011, 57:549-553. 10.1002/pbc.23040.
52. Strouse J.J., Fears T.R., Tucker M.A., Wayne A.S. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J. Clin. Oncol. 2005, 23:4735-4741. 10.1200/JCO.2005.02.899.
53. Tirode F., et al. Co-association between STAG2 and TP53 mutations defines an aggressive subgroup of Ewing Sarcoma. Cancer Discov. 2015, in press.
54. Trochet D., et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am. J. Hum. Genet. 2005, 76:421-426. 10.1086/428366.
55. Walkley C.R., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22:1662-1676. doi:22/12/1662 [pii]. 10.1101/gad.1656808.
56. Weiss W.A., Aldape K., Mohapatra G., Feuerstein B.G., Bishop J.M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997, 16:2985-2995.
57. Whiteman D.C., Valery P., McWhirter W., Green A.C. Risk factors for childhood melanoma in Queensland, Australia. Int. J. Cancer 1997, 70:26-31.
58. Williamson D., et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 2010, 28:2151-2158. doi:JCO.2009.26.3814 [pii]. 10.1200/JCO.2009.26.3814.
59. Wong J.R., Harris J.K., Rodriguez-Galindo C., Johnson K.J. Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 2013, 131:846-854. 10.1542/peds.2012-2520.
60. Zhang J., et al. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat. Genet. 2004, 36:351-360.
61. Zhang J., et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 2012, 481:329-334. 10.1038/nature10733.
62. Zhu S., et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell 2012, 21:362-373. 10.1016/j.ccr.2012.02.010.